FREQUENTLY ASKED QUESTIONS
What is the official ID of this bill?
The official print number for this legislation is 117_HR_7006.
Which chamber initiated this legislation?
This legislation was initiated in the House of Representatives.
When did the legislative process begin?
The process officially started on 2022-03-09.
What are the main provisions?
Key points include:
- Strengthening inspections of foreign drug factories, including considering the history of quality issues in a given country.
- Allowing the use of existing data and previous inspections for drug approvals, potentially speeding up availability.
- Increased cooperation with foreign governments on mutual recognition of inspections to streamline processes.
- A report to Congress evaluating the effectiveness of new inspection methods and opportunities for further development.
What is the specific legal status?
The current status is Expired.
Where can I read the full text of this legislation?
The full official text is available at:
View full text
Who is the primary sponsor?
The primary sponsor is Rep. Griffith, H. Morgan [R-VA-9].
What is the latest detailed status?
The latest detailed status is: Referred to the Subcommittee on Health.
Is this summary verified?
Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-28.
What is the impact of this bill?
We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge.